Michaël Peyromaure
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Michaël Peyromaure has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
Bernard Debré
7 shared publicationsMarc Zerbib
6 shared publications- Marc Zerbib
Service d'urologie, Hôpital Cochin, 27, rue du Faubourg Saint-Jacques, 75014 Paris, France
5 shared publications Bernard Debre
Department of Urology, Cochin Hospital, 27 rue du Faubourg Saint Jacques, 75014 Paris, France
3 shared publications- Vincent Ravery
Department of Urology, Bichat Hospital, Paris, France
3 shared publications - Anh Tuan Dinh-Xuan
Department of Respiratory and Sleep Medicine, Cochin Hospital, University Paris Cite, Paris, France
2 shared publications
Latest Publications
- 1 February 2017
- Published by Georg Thieme Verlag KG in Aktuelle Urologie
- Vol. 48 (01) , 14-17
Fusionsbiopsie der Prostata liefert zuverlässige Ergebnisse
Die transrektale Sonografie mit systematischer Biopsie gilt derzeit als Standard für die Diagnose eines Prostatakarzinoms. Allerdings ist das Verfahren nicht immer präzise – hochgradige Erkrankungen können übersehen und niedrig maligne Veränderungen übertherapiert werden. Die Fusionsbiopsie könnte eine Alternative darstellen, aber dazu muss sie zuverlässig reproduzierbar sein. Das haben Mediziner aus den USA geprüft.
- 1 February 2017
- Published by Georg Thieme Verlag KG in Aktuelle Urologie
- Vol. 48 (01) , 14-17
Fusionsbiopsie der Prostata liefert zuverlässige Ergebnisse
Die transrektale Sonografie mit systematischer Biopsie gilt derzeit als Standard für die Diagnose eines Prostatakarzinoms. Allerdings ist das Verfahren nicht immer präzise – hochgradige Erkrankungen können übersehen und niedrig maligne Veränderungen übertherapiert werden. Die Fusionsbiopsie könnte eine Alternative darstellen, aber dazu muss sie zuverlässig reproduzierbar sein. Das haben Mediziner aus den USA geprüft.
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51, S491
2547 Low abiraterone plasma concentration fails to induce PSA regression in metastatic castration-resistant prostate cancer patients
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51, S491
2547 Low abiraterone plasma concentration fails to induce PSA regression in metastatic castration-resistant prostate cancer patients
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , e15094
Impact of sarcopenia (Sp) on early dose-limiting toxicity (DLT) and acute vascular toxicity in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving sunitinib (SUT).
E15094 Background: mRCC pts with severe muscle wasting (Sp) are at increased risk of DLT during anti-VEGF therapy with sorafenib (Antoun et al., Ann Oncol 2010). We hypothesized that Sp could also predict SUT-induced toxicity. Methods: mRCC outpatients received SUT 50 mg OD (4/6 weeks) or 37.5 mg OD, from June 2006 to December 2010. From July 2008, SUT plasma levels were routinely monitored every 15 days. Skeletal muscle cross-sectional area at the third lumbar vertebra was measured by CT-scan, and Sp was defined using standardized thresholds. Blood pressure was monitored twice daily at home, and other toxicities were assessed every 15 days. The primary evaluation criterion was DLT during the first month. Secondary criteria were SUT AUC on day 28, acute vascular toxicities (thrombotic microangiopathy, TMA and reversible posterior leukoencephalopathy syndrome, RPLS) during treatment, and progression-free survival (PFS). Results: 45 pts (71.1% males, median age: 60.3 years, range 29-83) were eligible for CT-scan, toxicity and PFS analyses. Pharmacokinetic data were available for 16 pts. A total of 287 cycles (median/pt: 6, range 1-22) were given, for a median follow-up of 14.4 months (range: 1.5-51.3). During the first month, grade 3 hypertension (not dose-limiting) occurred in 11 pts (24.4%), and DLT occurred in 8 pts (17.8%), including grade 3 fatigue (3 pts, 6.7%), TMA and RPLS (2 pts each, 4.4%), grade 3 hand-foot syndrome and pulmonary embolism (1 pt each, 2.2%). 22 pts (48.9%) had Sp at baseline. Pts with Sp experienced significantly more DLTs during the first month of treatment (7/22 vs. 1/23, p = 0.02). SUT AUC on day 28 (median: 1599 vs. 1228 ng.h/ml, p = 0.12) and PFS (median: 8.0 vs. 8.5 months, p = 0.29) did not differ between pts with or without Sp. Of 7 pts who experienced TMA or RPLS during the whole treatment period, 6 (86%) had Sp at baseline. Conclusions: mRCC pts with Sp receiving SUT are at higher risk of early DLT, and experience more frequently acute vascular toxicities (TMA and RPLS). Sp appears to be a marker of tissular vulnerability that deserves further validation on larger cohorts of pts receiving anti-VEGF agents.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , e15094
Impact of sarcopenia (Sp) on early dose-limiting toxicity (DLT) and acute vascular toxicity in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving sunitinib (SUT).
E15094 Background: mRCC pts with severe muscle wasting (Sp) are at increased risk of DLT during anti-VEGF therapy with sorafenib (Antoun et al., Ann Oncol 2010). We hypothesized that Sp could also predict SUT-induced toxicity. Methods: mRCC outpatients received SUT 50 mg OD (4/6 weeks) or 37.5 mg OD, from June 2006 to December 2010. From July 2008, SUT plasma levels were routinely monitored every 15 days. Skeletal muscle cross-sectional area at the third lumbar vertebra was measured by CT-scan, and Sp was defined using standardized thresholds. Blood pressure was monitored twice daily at home, and other toxicities were assessed every 15 days. The primary evaluation criterion was DLT during the first month. Secondary criteria were SUT AUC on day 28, acute vascular toxicities (thrombotic microangiopathy, TMA and reversible posterior leukoencephalopathy syndrome, RPLS) during treatment, and progression-free survival (PFS). Results: 45 pts (71.1% males, median age: 60.3 years, range 29-83) were eligible for CT-scan, toxicity and PFS analyses. Pharmacokinetic data were available for 16 pts. A total of 287 cycles (median/pt: 6, range 1-22) were given, for a median follow-up of 14.4 months (range: 1.5-51.3). During the first month, grade 3 hypertension (not dose-limiting) occurred in 11 pts (24.4%), and DLT occurred in 8 pts (17.8%), including grade 3 fatigue (3 pts, 6.7%), TMA and RPLS (2 pts each, 4.4%), grade 3 hand-foot syndrome and pulmonary embolism (1 pt each, 2.2%). 22 pts (48.9%) had Sp at baseline. Pts with Sp experienced significantly more DLTs during the first month of treatment (7/22 vs. 1/23, p = 0.02). SUT AUC on day 28 (median: 1599 vs. 1228 ng.h/ml, p = 0.12) and PFS (median: 8.0 vs. 8.5 months, p = 0.29) did not differ between pts with or without Sp. Of 7 pts who experienced TMA or RPLS during the whole treatment period, 6 (86%) had Sp at baseline. Conclusions: mRCC pts with Sp receiving SUT are at higher risk of early DLT, and experience more frequently acute vascular toxicities (TMA and RPLS). Sp appears to be a marker of tissular vulnerability that deserves further validation on larger cohorts of pts receiving anti-VEGF agents.
- 1 June 2006
- Vol. 16 (3) , 378-80
[Sarcomatoid carcinoma with heterologous osteoid differentiation].
Sarcomatoid carcinomas of the bladder with heterologous osteoid differentiation are exceptional, aggressive tumors with a poor prognosis. We report a new case, and discuss the clinical and pathological characteristics of this tumor.
- 1 June 2006
- Vol. 16 (3) , 378-80
[Sarcomatoid carcinoma with heterologous osteoid differentiation].
Sarcomatoid carcinomas of the bladder with heterologous osteoid differentiation are exceptional, aggressive tumors with a poor prognosis. We report a new case, and discuss the clinical and pathological characteristics of this tumor.
- 31 December 2005
- Published by Elsevier in Medical Hypotheses
- Vol. 64 (1) , 92-95
Pro PSA : a “pro cancer” form of PSA?
- 31 December 2005
- Published by Elsevier in Medical Hypotheses
- Vol. 64 (1) , 92-95
Pro PSA : a “pro cancer” form of PSA?
- 24 November 2005
- Vol. 39 (3)
[Intermittent hormone therapy for prostate cancer].
- 1 November 2005
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 174 (5) , 1794-1797
MANAGEMENT OF PROSTATE CANCER IN CHINA: A MULTICENTER REPORT OF 6 INSTITUTIONS
In China the incidence of prostate cancer (PCa) is low and sparse data are available regarding its management. We analyzed the management of PCa at 6 Chinese urological institutions. A retrospective analysis was performed of 431 consecutive patients treated for PCa at 6 Chinese institutions, including 5 in the divisions of Shanghai and 1 in the province of Chongqing, between January 2000 and December 2004. Tumor characteristics, therapeutic options and patient outcomes were recorded. At diagnosis median patient age was 72 years and median prostate specific antigen was 46.1 ng/ml. Most PCa cases were revealed by urinary symptoms (75.9%) or bone pain (12.8%). PCa was palpable on digital rectal examination in 74% of cases. At least 44 patients (10.2%) had metastases to lymph nodes at diagnosis and 112 (26%) had bone metastases. A total of 236 patients underwent bilateral orchiectomy and 100 received medical hormone therapy, which in 75% consisted of antiandrogen alone. At a median followup of 16.8 months 60% of these patients experienced biological recurrence. Radical prostatectomy was performed in 24 patients as monotherapy or in combination with bilateral orchiectomy. No patient with clinically localized PCa experienced biological recurrence after radical prostatectomy. The management of PCa in China differs from that in Western countries. To date surgical castration represents standard treatment. Screening detection of PCa could help detect earlier stage tumors and improve the outcome in patients.
- 1 November 2005
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 174 (5) , 1794-1797
MANAGEMENT OF PROSTATE CANCER IN CHINA: A MULTICENTER REPORT OF 6 INSTITUTIONS
In China the incidence of prostate cancer (PCa) is low and sparse data are available regarding its management. We analyzed the management of PCa at 6 Chinese urological institutions. A retrospective analysis was performed of 431 consecutive patients treated for PCa at 6 Chinese institutions, including 5 in the divisions of Shanghai and 1 in the province of Chongqing, between January 2000 and December 2004. Tumor characteristics, therapeutic options and patient outcomes were recorded. At diagnosis median patient age was 72 years and median prostate specific antigen was 46.1 ng/ml. Most PCa cases were revealed by urinary symptoms (75.9%) or bone pain (12.8%). PCa was palpable on digital rectal examination in 74% of cases. At least 44 patients (10.2%) had metastases to lymph nodes at diagnosis and 112 (26%) had bone metastases. A total of 236 patients underwent bilateral orchiectomy and 100 received medical hormone therapy, which in 75% consisted of antiandrogen alone. At a median followup of 16.8 months 60% of these patients experienced biological recurrence. Radical prostatectomy was performed in 24 patients as monotherapy or in combination with bilateral orchiectomy. No patient with clinically localized PCa experienced biological recurrence after radical prostatectomy. The management of PCa in China differs from that in Western countries. To date surgical castration represents standard treatment. Screening detection of PCa could help detect earlier stage tumors and improve the outcome in patients.
- 21 June 2005
- Published by Elsevier in Annales d'Urologie
- Vol. 39 (3-4) , 116-123
Traitement hormonal intermittent du cancer prostatique : état actuel des connaissances
- 21 June 2005
- Published by Elsevier in Annales d'Urologie
- Vol. 39 (3-4) , 116-123
Traitement hormonal intermittent du cancer prostatique : état actuel des connaissances